Mesothelioma Center at Loyola Will Grow Under Vigneswaran

Renowned thoracic surgeon Dr. Wickii Vigneswaran left the Loyola University Health System 10 years ago to help start the lung transplant program at nearby University of Chicago Medical Center. He returned to Loyola this year to direct a mesothelioma specialty center, bringing his decade of experience from one of the country's finest research facilities. "I've got the best of both worlds now, and I think patients will really benefit from that," Vigneswaran told Asbestos.com. "We'll continue to collaborate with the best researchers, but now I'll have a broader clinical base at Loyola. It's a win-win situation for everyone." Vigneswaran performed more than 200 surgeries for mesothelioma patients, along with the lung transplants, during his 10 years at the Chicago Medical Center. He did the aggressive extrapleural pneumonectomy (EPP) and the lung sparing but more detailed pleurectomy/decortication (P/D) surgeries. He earned his reputation there as one of America's finest mesothelioma specialists. He returned to the Loyola School of Medicine as professor and chief of thoracic and cardiovascular surgery, starting the new year at his old place of employment. "My goal now is to build a really robust [mesothelioma] program at Loyola, both clinically and academically. I'm really excited about coming back and utilizing the great resources we have here," he said. "When you make a move like this, it allows you to think outside the box a li...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

Some of the nation’s top mesothelioma specialists are scheduled to share their expertise at the 2019 International Symposium on Malignant Mesothelioma. The event, organized by the Mesothelioma Applied Research Foundation, will be held March 24-27 in Bethesda, Maryland. The three-day symposium consists of two days of conference sessions and an advocacy day March 27. Mesothelioma patients, caregivers, family members and the bereaved community are invited to attend and learn about the latest treatment options for this rare cancer. “The symposium is a unique event for mesothelioma patients, their families and careg...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The National Cancer Institute awarded a five-year, $10.7 million grant to the Abramson Cancer Center at the University of Pennsylvania to develop CAR T-cell therapy for mesothelioma and lung cancer. The hopes are high for a breakthrough. The program involves a laboratory modification of a patient’s T cells — a type of white blood cell — that prompts the immune system to attack cancer cells. The therapy also is known as chimeric antigen receptor T-cell therapy. It already is revolutionizing the way some blood and bone marrow cancers are treated. The grant is designed to investigate whether this type of gen...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Melaiu O, Gemignani F, Landi S Abstract Malignant pleural mesothelioma (MPM) is a cancer of the pleural cavity whose main risk factor is exposure to asbestos. However, it has been shown that only a minority of exposed people develops MPM. In fact, the incidence among professionally exposed workers was shown to vary between 0.5% and 18.0%. Various hints suggested that other important cofactors could play a role, in particular the genetic susceptibility. Impressive is the case of Cappadocians families exposed to erionite and affected by an "epidemic" of MPM with about half of the inhabitants dying ...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Consumer products giant Colgate-Palmolive once again is paying for the alleged link between the company’s Cashmere Bouquet talcum powder and deadly asbestos exposure. The New York-based company agreed to settle a lawsuit claiming a Pennsylvania woman developed mesothelioma after using the talcum powder product for more than 20 years. Colgate-Palmolive avoided a trial in a New Jersey state court with the undisclosed settlement Oct. 30, according to court filings. Plaintiff Carol Schoeniger alleged the company failed to warn her of risks associated with using Cashmere Bouquet, claiming inhaling the asbestos-contaminate...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: asbestos exposure asbestos-contaminated talc California Court of Appeal Carol Schoeniger Cashmere Bouquet Colgate-Palmolive Gwen Myers Idee Fox Imerys Talc North America Johnson & Johnson Judith Winkel Los Angeles Superior Court Ma Source Type: news
Conclusion For patients with rare tumors, CRS and HIPEC is feasible with an acceptable perioperative morbidity and mortality. To improve knowledge in patient selection and outcome, rare tumors treated with CRS and HIPEC should be documented in central databases (as for example BIG RENAPE, Pierre-Benite, France).
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential. The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy. A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-lin...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news
Conclusions Long-term regional chemotherapy was associated with improved survival in patients with MPM. In this rare disease, additional phase 2 investigations are suggested. Teaser Synopsis: Malignant peritoneal mesothelioma was treated over a 20 year time period with a consistent surgical procedure followed by an escalation of regional chemotherapy treatments. When regional chemotherapy long term was added to the treatment plan survival improved significantly (p=0.0108).
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
An international research team is exploring how variants of an important blood protein could be the key to prevention and early detection of malignant mesothelioma. Dr. Haining Yang at the University of Hawaii Cancer Center is leading the research and recently presented potential strategies at the 6th International Symposium on Malignant Pleural Mesothelioma. Previously, Yang and her team showed how the High-Mobility Group Box 1 (HMGB1) protein sparks the proliferation and survival of cancerous mesothelioma cells. Yang and colleagues recently discovered that isoforms or “protein variants” of HMGB1 could be a ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: early detection of mesothelioma early diagnosis of mesothelioma early mesothelioma diagnosis hmgb1 isoforms malignant pleural mesothelioma mesothelioma research mesothelioma survival Source Type: news
By Stacy Simon The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society. The cancer death rate for men and women combined fell 25% from its peak in 1991 to 2014, the most recent year for which data are available. This decline translates to more than 2.1 million deaths averted during this time period. “Cancer Statistics, 2017,” published in the American Cancer Society’s journal CA: A Cancer Journal for Clinicians, estimates the numbers of new cancer cases and deaths expected in the US this year. The estimat...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: General Information Source Type: news
Radiologists at the UCLA Medical Center are successfully killing tumor cells with extreme cold, also known as cryoablation, in patients with recurrent pleural mesothelioma. An outpatient procedure with few complications, cryoablation freezes the localized tumors with argon gas or liquid nitrogen, allowing patients to fight the almost-inevitable cancer recurrence after surgery. Dr. Fereidoun Abtin, a UCLA radiologist who performs the procedure, told Asbestos.com he is “convinced it works well for these patients.” “The results have been impressive, a lot better than what else is out there in the literature ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: cryoablation for cancer cryoablation for mesothelioma cryosurgery for mesothelioma cryotherapy for mesothelioma freezing cancer tumors mesothelioma treatment Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Employment | Environmental Health | Gene Therapy | Genetics | Health | Health Management | Heart | Hospitals | Immunotherapy | Lung Transplant | Mesothelioma | Rare Diseases | Study | Transplant Surgery | Transplants